share_log

Chemours Analyst Ratings

Chemours Analyst Ratings

Chemours 分析師評級
Benzinga ·  2023/10/30 09:25
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/30/2023 18.74% Barclays $31 → $28 Maintains Equal-Weight
10/04/2023 31.47% Barclays $40 → $31 Maintains Equal-Weight
08/02/2023 124.77% BMO Capital $64 → $53 Maintains Outperform
08/01/2023 39.95% Morgan Stanley $33 → $33 Reiterates Equal-Weight → Equal-Weight
07/31/2023 69.64% RBC Capital $37 → $40 Maintains Sector Perform
07/19/2023 39.95% Morgan Stanley $33 → $33 Reiterates Equal-Weight → Equal-Weight
07/11/2023 69.64% Barclays $38 → $40 Maintains Equal-Weight
06/22/2023 56.91% B of A Securities $41 → $37 Downgrades Buy → Neutral
06/13/2023 82.36% UBS $41 → $43 Maintains Buy
06/09/2023 56.91% RBC Capital $36 → $37 Maintains Sector Perform
06/05/2023 171.42% BMO Capital $54 → $64 Maintains Outperform
05/31/2023 27.23% JP Morgan $35 → $30 Maintains Neutral
05/01/2023 52.67% RBC Capital $35 → $36 Maintains Sector Perform
05/01/2023 129.01% BMO Capital $52 → $54 Maintains Outperform
04/28/2023 6.02% Credit Suisse $27 → $25 Maintains Underperform
02/14/2023 61.15% Goldman Sachs $34 → $38 Maintains Neutral
02/13/2023 48.43% Citigroup $33 → $35 Maintains Neutral
02/13/2023 52.67% RBC Capital $33 → $36 Maintains Sector Perform
02/10/2023 14.5% Credit Suisse $24 → $27 Maintains Underperform
01/24/2023 82.36% UBS $31 → $43 Upgrades Neutral → Buy
01/11/2023 31.47% UBS $29 → $31 Maintains Neutral
01/11/2023 69.64% B of A Securities $37 → $40 Upgrades Neutral → Buy
01/10/2023 39.95% RBC Capital $35 → $33 Downgrades Outperform → Sector Perform
12/15/2022 39.95% Citigroup $30 → $33 Maintains Neutral
11/01/2022 1.78% Credit Suisse → $24 Initiates Coverage On → Underperform
10/27/2022 73.88% BMO Capital $46 → $41 Maintains Outperform
10/25/2022 39.95% Morgan Stanley $41 → $33 Maintains Equal-Weight
10/13/2022 27.23% Goldman Sachs → $30 Initiates Coverage On → Neutral
10/05/2022 — Argus Research Downgrades Buy → Hold
09/27/2022 27.23% Barclays $46 → $30 Maintains Equal-Weight
09/23/2022 95.08% BMO Capital $55 → $46 Maintains Outperform
09/22/2022 48.43% RBC Capital $48 → $35 Maintains Outperform
08/01/2022 103.56% RBC Capital $44 → $48 Maintains Outperform
07/29/2022 56.91% UBS $35 → $37 Maintains Neutral
06/14/2022 86.6% B of A Securities $48 → $44 Downgrades Buy → Neutral
05/09/2022 73.88% Morgan Stanley $35 → $41 Maintains Equal-Weight
05/09/2022 95.08% Barclays $37 → $46 Maintains Equal-Weight
05/04/2022 103.56% RBC Capital $42 → $48 Maintains Outperform
02/15/2022 73.88% RBC Capital $44 → $41 Maintains Outperform
02/14/2022 27.23% JP Morgan $35 → $30 Maintains Neutral
01/04/2022 52.67% UBS $34 → $36 Maintains Neutral
11/08/2021 90.84% RBC Capital $40 → $45 Maintains Outperform
08/03/2021 69.64% RBC Capital $35 → $40 Maintains Outperform
06/10/2021 — Wolfe Research Initiates Coverage On → Outperform
06/09/2021 99.32% Goldman Sachs $35 → $47 Upgrades Neutral → Buy
05/20/2021 78.12% B of A Securities → $42 Initiates Coverage On → Buy
05/10/2021 48.43% Morgan Stanley $30 → $35 Maintains Equal-Weight
05/06/2021 69.64% Argus Research → $40 Upgrades Hold → Buy
02/16/2021 27.23% Morgan Stanley $28 → $30 Maintains Equal-Weight
01/08/2021 48.43% RBC Capital $27 → $35 Upgrades Sector Perform → Outperform
12/14/2020 18.74% Morgan Stanley $23 → $28 Maintains Equal-Weight
12/04/2020 18.74% Barclays $26 → $28 Downgrades Overweight → Equal-Weight
11/16/2020 -2.46% Morgan Stanley $12 → $23 Maintains Equal-Weight
11/05/2020 18.74% BMO Capital $26 → $28 Maintains Outperform
08/04/2020 -23.66% Citigroup $16 → $18 Maintains Neutral
08/03/2020 -19.42% RBC Capital $15 → $19 Maintains Sector Perform
07/09/2020 -36.39% UBS $12 → $15 Maintains Neutral
05/08/2020 -49.11% UBS $9 → $12 Maintains Neutral
05/07/2020 -49.11% SunTrust Robinson Humphrey $10 → $12 Maintains Hold
04/09/2020 -66.07% Citigroup $10 → $8 Maintains Neutral
04/03/2020 -53.35% CFRA $21 → $11 Downgrades Strong Buy → Hold
04/01/2020 -53.35% RBC Capital $13 → $11 Maintains Sector Perform
03/30/2020 -49.11% Morgan Stanley $15 → $12 Maintains Equal-Weight
03/26/2020 -10.94% BMO Capital $33 → $21 Maintains Outperform
02/18/2020 -19.42% SunTrust Robinson Humphrey $17 → $19 Maintains Hold
12/20/2019 -19.42% JP Morgan $21 → $19 Maintains Neutral
11/07/2019 6.02% BMO Capital $23 → $25 Maintains Outperform
11/06/2019 -10.94% Citigroup $14 → $21 Maintains Neutral
10/02/2019 -38.51% UBS $19 → $14.5 Maintains Neutral
09/09/2019 -2.46% BMO Capital $31 → $23 Maintains Outperform
08/20/2019 -23.66% Susquehanna $37 → $18 Upgrades Neutral → Positive
08/09/2019 — RBC Capital Downgrades Outperform → Sector Perform
08/06/2019 — Argus Research Downgrades Buy → Hold
08/05/2019 31.47% BMO Capital $45 → $31 Maintains Outperform
05/06/2019 — JP Morgan Downgrades Overweight → Neutral
04/15/2019 120.53% SunTrust Robinson Humphrey → $52 Upgrades Hold → Buy
02/19/2019 — Susquehanna Downgrades Positive → Neutral
11/05/2018 145.97% BMO Capital $68 → $58 Maintains Outperform
11/02/2018 61.15% Citigroup $44 → $38 Downgrades Buy → Neutral
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
2023年10月30日 18.74% 巴克萊 $31→$28 維護 等重
10/04/2023 31.47% 巴克萊 $40→$31 維護 等重
08/02/2023 124.77% 蒙特利爾銀行資本 $64→$53 維護 跑贏大盤
08/01/2023 39.95% 摩根士丹利 $33→$33 重申 等重→等重
07/31/2023 69.64% 加拿大皇家銀行資本 $37→$40 維護 行業表現
07/19/2023 39.95% 摩根士丹利 $33→$33 重申 等重→等重
07/11/2023 69.64% 巴克萊 $38→$40 維護 等重
2023/06/22 56.91% B of A證券 $41→$37 評級下調 購買→中性
2023/06/13 82.36% 瑞銀集團 $41→$43 維護 買
06/09/2023 56.91% 加拿大皇家銀行資本 $36→$37 維護 行業表現
06/05/2023 171.42% 蒙特利爾銀行資本 $54→$64 維護 跑贏大盤
2023年05月31日 27.23% 摩根大通 $35→$30 維護 中性
05/01/2023 52.67% 加拿大皇家銀行資本 $35→$36 維護 行業表現
05/01/2023 129.01% 蒙特利爾銀行資本 $52→$54 維護 跑贏大盤
04/28/2023 6.02% 瑞士信貸 $27→$25 維護 表現不佳
02/14/2023 61.15% 高盛 $34→$38 維護 中性
02/13/2023 48.43% 花旗集團 $33→$35 維護 中性
02/13/2023 52.67% 加拿大皇家銀行資本 $33→$36 維護 行業表現
02/10/2023 14.5% 瑞士信貸 $24→$27 維護 表現不佳
01/24/2023 82.36% 瑞銀集團 $31→$43 升級 中性→購買
2023年1月11日 31.47% 瑞銀集團 $29→$31 維護 中性
2023年1月11日 69.64% B of A證券 $37→$40 升級 中性→購買
2023年1月10日 39.95% 加拿大皇家銀行資本 $35→$33 評級下調 跑贏→板塊表現
2022年12月15日 39.95% 花旗集團 $30→$33 維護 中性
11/01/2022 1.78% 瑞士信貸 →$24 開始承保 →表現不佳
10/27/2022 73.88% 蒙特利爾銀行資本 $46→$41 維護 跑贏大盤
2022年10月25日 39.95% 摩根士丹利 $41→$33 維護 等重
10/13/2022 27.23% 高盛 →$30 開始承保 →中性
10/05/2022 - Argus研究 評級下調 購買→Hold
09/27/2022 27.23% 巴克萊 $46→$30 維護 等重
09/23/2022 95.08% 蒙特利爾銀行資本 $55→$46 維護 跑贏大盤
09/22/2022 48.43% 加拿大皇家銀行資本 $48→$35 維護 跑贏大盤
08/01/2022 103.56% 加拿大皇家銀行資本 $44→$48 維護 跑贏大盤
07/29/2022 56.91% 瑞銀集團 $35→$37 維護 中性
2022/06/14 86.6% B of A證券 $48→$44 評級下調 購買→中性
05/09/2022 73.88% 摩根士丹利 $35→$41 維護 等重
05/09/2022 95.08% 巴克萊 $37→$46 維護 等重
05/04/2022 103.56% 加拿大皇家銀行資本 $42→$48 維護 跑贏大盤
02/15/2022 73.88% 加拿大皇家銀行資本 $44→$41 維護 跑贏大盤
02/14/2022 27.23% 摩根大通 $35→$30 維護 中性
01/04/2022 52.67% 瑞銀集團 $34→$36 維護 中性
11/08/2021 90.84% 加拿大皇家銀行資本 $40→$45 維護 跑贏大盤
08/03/2021 69.64% 加拿大皇家銀行資本 $35→$40 維護 跑贏大盤
2021/10/06 - 沃爾夫研究 開始承保 →跑贏大盤
06/09/2021 99.32% 高盛 $35→$47 升級 中性→購買
05/20/2021 78.12% B of A證券 →$42 開始承保 →購買
2021/05/10 48.43% 摩根士丹利 $30→$35 維護 等重
05/06/2021 69.64% Argus研究 →$40 升級 持有→購買
02/16/2021 27.23% 摩根士丹利 $28→$30 維護 等重
01/08/2021 48.43% 加拿大皇家銀行資本 $27→$35 升級 行業表現優於→
12/14/2020 18.74% 摩根士丹利 $23→$28 維護 等重
12/04/2020 18.74% 巴克萊 $26→$28 評級下調 超重→等重
11/16/2020 -2.46% 摩根士丹利 $12→$23 維護 等重
11/05/2020 18.74% 蒙特利爾銀行資本 $26→$28 維護 跑贏大盤
08/04/2020 -23.66% 花旗集團 $16→$18 維護 中性
08/03/2020 -19.42% 加拿大皇家銀行資本 $15→$19 維護 行業表現
07/09/2020 -36.39% 瑞銀集團 $12→$15 維護 中性
05/08/2020 -49.11% 瑞銀集團 $9→$12 維護 中性
05/07/2020 -49.11% SunTrust Robinson Humphrey $10→$12 維護 保持
04/09/2020 -66.07% 花旗集團 $10→$8 維護 中性
04/03/2020 -53.35% CFRA $21→$11 評級下調 強力買入→Hold
04/01/2020 -53.35% 加拿大皇家銀行資本 $13→$11 維護 行業表現
03/30/2020 -49.11% 摩根士丹利 $15→$12 維護 等重
03/26/2020 -10.94% 蒙特利爾銀行資本 $33→$21 維護 跑贏大盤
02/18/2020 -19.42% SunTrust Robinson Humphrey $17→$19 維護 保持
2019年12月20日 -19.42% 摩根大通 $21→$19 維護 中性
2019/07/11 6.02% 蒙特利爾銀行資本 $23→$25 維護 跑贏大盤
2019/06/11 -10.94% 花旗集團 $14→$21 維護 中性
2019年10月02日 -38.51% 瑞銀集團 $19→$14.5 維護 中性
2019年09月09日 -2.46% 蒙特利爾銀行資本 $31→$23 維護 跑贏大盤
2019年08月20日 -23.66% 薩斯奎哈納 $37→$18 升級 中性→陽性
2019年08月09日 - 加拿大皇家銀行資本 評級下調 跑贏→板塊表現
2019年08月06日 - Argus研究 評級下調 購買→Hold
2019年08月05日 31.47% 蒙特利爾銀行資本 $45→$31 維護 跑贏大盤
2019年05月06日 - 摩根大通 評級下調 超重→中性
2019年04月15日 120.53% SunTrust Robinson Humphrey →$52 升級 持有→購買
2019年02月19日 - 薩斯奎哈納 評級下調 正→中性
2018年11月05日 145.97% 蒙特利爾銀行資本 $68→$58 維護 跑贏大盤
11/02/2018 61.15% 花旗集團 $44→$38 評級下調 購買→中性

What is the target price for Chemours (CC)?

化學(CC)的目標價格是多少？

The latest price target for Chemours (NYSE: CC) was reported by Barclays on October 30, 2023. The analyst firm set a price target for $28.00 expecting CC to rise to within 12 months (a possible 18.74% upside). 25 analyst firms have reported ratings in the last year.

巴克萊銀行於2023年10月30日報告了科慕（NYSE：CC）的最新目標價。該分析公司將價格目標定為28.00美元，預計CC將在12個月內上漲（可能上漲18.74%）。去年有25家分析公司公佈了評級。

What is the most recent analyst rating for Chemours (CC)?

化學(CC)的最新分析師評級是多少？

The latest analyst rating for Chemours (NYSE: CC) was provided by Barclays, and Chemours maintained their equal-weight rating.

最新的分析師對化學(紐約證券交易所代碼：CC)的評級是由巴克萊提供的，化學維持其同等權重的評級。

When is the next analyst rating going to be posted or updated for Chemours (CC)?

化學(CC)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Chemours, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Chemours was filed on October 30, 2023 so you should expect the next rating to be made available sometime around October 30, 2024.

分析師在做了廣泛的研究後得出了股票評級，研究內容包括查閱公開財務報表、與科慕的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月做一次，所以你每年應該對每家公司進行4次評級。Chemours的最後一次評級於2023年10月30日提交，因此您應該期待下一次評級將於2024年10月30日左右提供。

Is the Analyst Rating Chemours (CC) correct?

分析師對化學(CC)的評級正確嗎？

While ratings are subjective and will change, the latest Chemours (CC) rating was a maintained with a price target of $31.00 to $28.00. The current price Chemours (CC) is trading at is $23.58, which is out of the analyst's predicted range.

雖然評級是主觀的，會發生變化，但最新的科慕（CC）評級是維持在31.00美元至28.00美元的目標價格。Chemours（CC）目前的交易價格為23.58美元，超出了分析師的預測範圍。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論